ElastoMeric Infusion Pumps for Hospital AntibioTICs (EMPHATIC)
Primary Purpose
Infection, Bacterial
Status
Active
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
To assess the feasibility of giving intravenous antibiotics to adult inpatients using elastomeric infusion pumps (EMPs)
Sponsored by
About this trial
This is an interventional device feasibility trial for Infection, Bacterial
Eligibility Criteria
Inclusion Criteria:
- Adult patients 18 years and over admitted to hospital with an infection requiring treatment for 7 days or more with intravenous flucloxacillin, piperacillin/tazobactam or benzylpenicillin Clinically stable and improving as assessed by the hospital medical consultant and likely to be well enough for discharge in the next two weeks.
Able to provide written consent or witnessed consent
Exclusion Criteria:
- Unable to receive an appropriate vascular access device, such as a peripherally inserted central catheter (PICC) Penicillin allergy and unsuitable to receive penicillin challenge or desensitisation.
Requires a combination of intravenous antibiotics, any of which needs to be given more often than once daily.
Requires transfer to another hospital Unsuitable for outpatient parenteral antibiotic treatment
Sites / Locations
- Mid Yorkshire Hospitals NHS Trust
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Number of consented patients who complete the antibiotics through an elastomeric pump
Arm Description
Flucloxacillin, piperacillin/taozbactam and benzylpenicillin will be use
Outcomes
Primary Outcome Measures
Number (%) of consented inpatients who complete the planned course of intravenous antibiotics through an EMP
Secondary Outcome Measures
Number (%) of screened patients as identified by a microbiologist, antimicrobial pharmacist or the patient's clinical team
Number (%) of screened patients consented (recruitment)
Number (%) of consented patients who receive ≥1 dose of EMP
Time (hrs) from electronic prescribing (with planned start date) of initial intravenous antibiotic to administration of first dose through EMP
Time (hrs) from identification of medically fit for discharge to actual discharge
Duration of hospital inpatient stay (days)
Time (minutes) to order, procure, deliver and administer EMPs
Clinical cure (resolution of symptoms) assessed by hospital medical consultant
30-day mortality
High residual volume in EMP (greater than 15% of 240mL = 36mL)
Duration of total antibiotic course (days), including any early termination of planned treatment course and reason
Description of antibiotic treatment pathway: intermittent, EMP, outpatient parenteral antibiotic therapy (OPAT), oral, cease
Number of intravascular access devices required, including intermittent infusion period and EMP period
Number (%) of missed and delayed doses from beginning of antibiotic course, either with intermittent infusion or EMP
Time taken (hrs) to order, procure, deliver and administer antibiotics through EMPs
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05150015
Brief Title
ElastoMeric Infusion Pumps for Hospital AntibioTICs
Acronym
EMPHATIC
Official Title
ElastoMeric Infusion Pumps for Hospital AntibioTICs
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
May 7, 2022 (Actual)
Primary Completion Date
December 1, 2022 (Actual)
Study Completion Date
December 1, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Stuart Bond
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Special pumps called self-deflating Elastomeric Pumps (EMPs) will be tested for giving antibiotics via a drip to hospital patients. EMPs are filled with antibiotics, attached to a "drip" (usually in the arm) and worn on the body, slowly giving antibiotics through the day. EMPs are often used to give antibiotics to patients in their own home but they have not been used to treat patients in hospital before, so a small study of 10 patients will be conducted to see if a full scale clinical trial is worthwhile. EMPs will be tested for ease of use and safety in hospital, and to find out what staff and patients think about them. The pilot will be done to see if a clinical trial would be good value for money by comparing time spent in hospital, nursing time and overall cost to the NHS of the two ways of giving antibiotics to patients.
Detailed Description
4 Background 4.1 Antibiotic resistance Antibiotic resistance (AMR) is when bacteria have changed (mutated) so they can survive the effects of antibiotics, meaning antibiotics are less effective. AMR is a major threat to health worldwide. In UK hospitals, at least a third of patients are on antibiotics at any given time. Hospital patients with serious infections are often given intravenous antibiotics (through a "drip" into a vein). Cutting down unnecessary antibiotic prescribing is key to reducing resistance.
4.2 Problems giving intravenous antibiotics Giving intravenous antibiotics takes a lot of nursing time. This is made worse if antibiotics are needed more than once a day. Nurses are the only staff who give intravenous antibiotics in hospitals, and there is a shortage of 40,000 nurses in the NHS. Because of this, it is common for doses to be missed. The COVID-19 pandemic has increased the pressure on nurses' time. It is not always practical to give antibiotics 4 or 6 times a day so less effective antibiotics may be used instead.
4.3 What can be done to help? Some antibiotics work better when given slowly into a vein all the time. EMPs are self-powered devices that deliver antibiotics in this way.
EMPs:
are currently used to give antibiotics to patients in their own homes
are not used to give antibiotics to patients in hospitals because the safety, benefits and value for money have not been confirmed
could allow more nurse time for patient care by reducing the time to set up antibiotic drips.
could make things better for patients by allowing them to move more, sleep better, recover faster and spend less time in hospital
4.4 Designs and methods used Patients who could have antibiotics through EMPs will be identified from clinical ward rounds. EMPs will be tested for safety in hospital patients, as well as value for money in the NHS by collecting information about costs, nursing time and length of hospital stay. Surveys of patients and nursing staff will be conducted to explore how EMPs could be best used in hospital.
4.5 Patient and public involvement (PPI) This research has been driven by patients who know how difficult it is to keep mobile when attached to drip stands; how disturbed sleep from drips being set up in the night affects their wellbeing; and, how they are concerned about missed doses of antibiotics. The project has been designed with input from a PPI representative (Co-investigator Thompson) who has reviewed all project plans and materials.
4.6 Dissemination Findings will be published in medical journals and presented at conferences/NHS patient events. Social media will be used to let people know what is found and infographics will be developed to help communicate findings using social media. If appropriate, funding will be sought for a full trial.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infection, Bacterial
7. Study Design
Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Pilot feasability study
Masking
None (Open Label)
Allocation
N/A
Enrollment
9 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Number of consented patients who complete the antibiotics through an elastomeric pump
Arm Type
Experimental
Arm Description
Flucloxacillin, piperacillin/taozbactam and benzylpenicillin will be use
Intervention Type
Device
Intervention Name(s)
To assess the feasibility of giving intravenous antibiotics to adult inpatients using elastomeric infusion pumps (EMPs)
Intervention Description
Single arm study
Primary Outcome Measure Information:
Title
Number (%) of consented inpatients who complete the planned course of intravenous antibiotics through an EMP
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Number (%) of screened patients as identified by a microbiologist, antimicrobial pharmacist or the patient's clinical team
Time Frame
6 months
Title
Number (%) of screened patients consented (recruitment)
Time Frame
6 months
Title
Number (%) of consented patients who receive ≥1 dose of EMP
Time Frame
6 months
Title
Time (hrs) from electronic prescribing (with planned start date) of initial intravenous antibiotic to administration of first dose through EMP
Time Frame
6 months
Title
Time (hrs) from identification of medically fit for discharge to actual discharge
Time Frame
6 months
Title
Duration of hospital inpatient stay (days)
Time Frame
6 months
Title
Time (minutes) to order, procure, deliver and administer EMPs
Time Frame
6 months
Title
Clinical cure (resolution of symptoms) assessed by hospital medical consultant
Time Frame
6 months
Title
30-day mortality
Time Frame
6 months
Title
High residual volume in EMP (greater than 15% of 240mL = 36mL)
Time Frame
6 months
Title
Duration of total antibiotic course (days), including any early termination of planned treatment course and reason
Time Frame
6 months
Title
Description of antibiotic treatment pathway: intermittent, EMP, outpatient parenteral antibiotic therapy (OPAT), oral, cease
Time Frame
6 months
Title
Number of intravascular access devices required, including intermittent infusion period and EMP period
Time Frame
6 months
Title
Number (%) of missed and delayed doses from beginning of antibiotic course, either with intermittent infusion or EMP
Time Frame
6 months
Title
Time taken (hrs) to order, procure, deliver and administer antibiotics through EMPs
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult patients 18 years and over admitted to hospital with an infection requiring treatment for 7 days or more with intravenous flucloxacillin, piperacillin/tazobactam or benzylpenicillin Clinically stable and improving as assessed by the hospital medical consultant and likely to be well enough for discharge in the next two weeks.
Able to provide written consent or witnessed consent
Exclusion Criteria:
Unable to receive an appropriate vascular access device, such as a peripherally inserted central catheter (PICC) Penicillin allergy and unsuitable to receive penicillin challenge or desensitisation.
Requires a combination of intravenous antibiotics, any of which needs to be given more often than once daily.
Requires transfer to another hospital Unsuitable for outpatient parenteral antibiotic treatment
Facility Information:
Facility Name
Mid Yorkshire Hospitals NHS Trust
City
Wakefield
State/Province
West Yorkshire
ZIP/Postal Code
WF14DG
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
ElastoMeric Infusion Pumps for Hospital AntibioTICs
We'll reach out to this number within 24 hrs